Race Oncology Limited
RAONF
Other OTC2.60
USD
+1.38
- -
ISIN
AU000000RAC3
Return %
Stock
S&P500
1Y
113.11
26.84
3Y
79.31
77.03
5Y
-16.13
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel Tillett
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Gateway, 1 Macquarie Place Sydney NSW Australia 2000
- IPO Date
- Mar 9, 2021
- Website
- raceoncology.com
- Similar Companies
- Business
- Race Oncology Limited (ASX:RAC; OTC:RAONF) is an Australia-based clinical-stage biopharmaceutical company focused on developing novel oncology treatments that address unmet needs in cancer care by enhancing anticancer efficacy and reducing cardiotoxicity. Founded in 2011 and headquartered at Level 36, 1 Macquarie Place, Sydney, New South Wales, the company develops RC220, a proprietary reformulated version of bisantrene, a small-molecule chemotherapeutic originally evaluated in over 50 clinical trials involving more than 1,500 patients; RC220 targets G4-DNA and RNA binding to inhibit the MYC cancer growth regulator, demonstrates lower cardiotoxicity than anthracyclines like doxorubicin, and shows potential cardioprotection when combined with anthracyclines in solid tumors including breast cancer and non-small cell lung cancer, as well as acute myeloid leukemia (AML). Its pipeline emphasizes anthracycline combination therapies for advanced solid tumors, m6A RNA pathway modulation via FTO inhibition, and next-generation FTO inhibitor candidates discovered through fragment-based screening at Monash University. The company conducts Phase 1 clinical trials, such as RAC-010 evaluating RC220 plus doxorubicin safety, tolerability, and pharmacokinetics in advanced solid tumor patients at sites including Southside Cancer Care Centre in New South Wales, with expansion into Asia featuring open sites in Hong Kong and forthcoming recruitment in South Korea; it plans Phase 2b CPACS-2, Phase 3 AML efficacy expansion, and HARNESS-1 lung cancer trials starting in Q1 2026. Race Oncology collaborates with global institutions including Astex, City of Hope, MD Anderson Cancer Center, Sheba Medical Center, UNC School of Medicine, University of Wollongong, and University of Newcastle, while actively pursuing additional partnerships, license agreements, or mergers to accelerate RC220 commercialization worldwide. Recent developments include execution of a contract in March 2025 with Emerald Clinical Trials (formerly George Clinical) for clinical operations support; appointments to strengthen leadership such as Professor Daniel Von Hoff to the Clinical Advisory Board and Dr. Jose Iglesias and Dr. Simon Fisher to medical roles, alongside Dr. Megan Baldwin as Independent Non-Executive Director effective January 2025 and board changes with Dr. Pete Smith as Chairman in August 2024; adoption of a new constitution at the 2025 AGM to enhance governance; receipt of $2.8 million R&D tax refund in November 2025 for FY2025 with further expected; breakthrough composition-of-matter IP discovery in September 2025; and financial positioning to fund ongoing trials through end-2027 while evaluating capital raises including option conversions. Operations remain centered in Australia with global clinical and research reach, targeting adult and pediatric cancer patients across multiple indications.
October inflation, jobs reports cancelled due to US government shutdown
Fed may skip December cut but leave door open for January, Deutsche Bank analysts say
Race Oncology launches new clinical programs in AML and lung cancer
Pensana shares up as it launches new drill and testing plans for Angola rare-earth project
Race Oncology makes significant quarterly progress in Phase 1 RC220 trial